Sanofi reports Q3 business EPS EUR 3.55, up 22% reported
Sanofi reported Q3 business EPS of EUR 3.55, up 22%, and net sales of EUR 14.4B, up 16.2%. CEO Belen Garijo cited strong sales growth driven by new medicines and Dupixent. The company raised its 2026 guidance, expecting low-teens sales growth and mid-teens business EPS growth. Sanofi also expanded its alliance with Regeneron and partnered with Cheplapharm to simplify its portfolio.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise are likely to trigger buying interest, especially among investors focused on pharma earnings momentum.
Market read
First‑report earnings and guidance lift for a large‑cap pharma, offering a clear short‑term trade idea.
What to watch
Potential cost pressures from R&D productivity initiatives could temper upside.
Background
Sanofi's Q3 results were released on Oct 30, 2026, highlighting strong sales growth and new guidance.
Ticker impact
Sanofi reported Q3 Business EPS of EUR 3.55, up 22% YoY and raised its 2026 guidance for sales and EPS growth.
potential upside as investors price in higher EPS growth expectations
The earnings beat and upward guidance are fresh primary disclosures for a large‑cap pharma, which typically drive short‑term buying pressure.
Market effects
Higher guidance may lift peer French and global pharma stocks.
Positive for European healthcare sector.
Adds to broader optimism in biotech/healthcare earnings season.
Counterpoint
If Dupixent faces generic competition sooner than expected, the guidance may be overly optimistic.
Key entities
- companySanofi
French multinational pharmaceutical company (ticker SNY).
- productDupixent
Key biologic driving sales growth.
